Virios Therapeutics (Virios Therapeutics) Price-to-Owner-Earnings : (As of Jun. 01, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-01), Virios Therapeutics's share price is $0.2183. Virios Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for Virios Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

VIRI's Price-to-Owner-Earnings is not ranked ^*
in the Biotechnology industry.
Industry Median: 32.61
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-01), Virios Therapeutics's share price is $0.2183. Virios Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.27. Therefore, Virios Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-01), Virios Therapeutics's share price is $0.2183. Virios Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.27. Therefore, Virios Therapeutics's PE Ratio without NRI for today is At Loss.

Virios Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Virios Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virios Therapeutics Price-to-Owner-Earnings Chart

Virios Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Owner-Earnings

Get a 7-Day Free Trial

Virios Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Owner-Earnings	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Virios Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Virios Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virios Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virios Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Virios Therapeutics's Price-to-Owner-Earnings falls into.

Virios Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Virios Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	0.2183	/	0.00
	=

Virios Therapeutics (NAS:VIRI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Virios Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Virios Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Virios Therapeutics (Virios Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Milton Avenue, Alpharetta, GA, USA, 30009

Website

https://www.virios.com

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.

Executives

William Pridgen	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan	director, officer: Chief Executive Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh	officer: VP of Finance	44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel	director	44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald	officer: Vice President of Operations	44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau	officer: Chief Medical Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch	director	44 MILTON AVENUE, ALPHARETTA GA 30009